Investigating how IL-33 affects lung injury after stem cell transplants in children

IL-33 induced-lL-9 producing type 2 innate lymphoid cells in the regulation of acute lung injury after hematopoietic stem cell transplantation (HSCT) in pediatric patients

NIH-funded research Medical University of South Carolina · NIH-10756116

This study is looking at how certain immune cells and a protein called IL-33 might cause lung problems in kids who have had a stem cell transplant, with the goal of finding better ways to help them breathe easier and stay healthy after their treatment.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMedical University of South Carolina NIH-funded
Lab location1 site (Charleston, United States)
Project IDNIH-10756116 on NIH RePORTER

What this research studies

This research focuses on understanding the role of IL-33 and type 2 innate lymphoid cells in causing lung injury following hematopoietic stem cell transplantation (HSCT) in pediatric patients. The study aims to identify mechanisms behind graft-versus-host disease (GVHD) and its impact on lung function, particularly in the context of acute lung injury. By exploring biomarkers and cellular interactions, the research seeks to develop better therapeutic strategies to mitigate these complications. Patients may be monitored for specific immune responses and lung health during and after their transplant.

Who could benefit from this research

Good fit: Ideal candidates for this research are pediatric patients who are undergoing or have undergone hematopoietic stem cell transplantation.

Not a fit: Patients who are not undergoing HSCT or have conditions unrelated to graft-versus-host disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments that reduce lung injury and enhance recovery for children undergoing stem cell transplants.

How similar studies have performed: Previous research has shown promising results in understanding immune responses related to GVHD, indicating potential for success in this area.

Where this research is happening

Charleston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.